REFERENCIAS: 1. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. Journal of Allergy and Clinical Immunology 2. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA 2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014.

REFERENCIAS: 1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. Disponible en: www.ginasthma.org. 2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management,
and prevention of chronic obstructive pulmonary disease. 2021 report. Disponible en: www.goldcopd.org. 3. Ramakrishnan S, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. The Lancet Respiratory Medicine 2021. 4. Bronsky EA, et al. Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults. Current Medical Research and Opinion 2004. 5. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of Handling of Inhaler Devices in Real Life: An Observational Study in 3811 Patients in Primary Care. Journal of Aerosol Medicine 2003. 6. Molimard M. How to achieve good compliance and adherence with inhalation therapy. Current Medical Research and Opinion 2005. 7. Data on File. Novamed.

REFERENCIAS: 1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. Disponible en: www.ginasthma.org. 2. Wise SK, et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis: ICAR: Allergic Rhinitis. International Forum of Allergy & Rhinology. 2018. 3. Bousquet J, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology 2020. 4. Data on file. Novamed.

REFERENCIAS: 1. AZITROMICINA EN VADEMECUM [Internet]. [citado 2021 ago 10];Available from: https://www.iqb.es/cbasicas/farma/farma04/a064.htm. 2. FICHA TECNICA CLARITROMICINA NORMON 500 mg COMPRIMIDOS RECUBIERTOS EFG [Internet]. [citado 2021 ago 10];Available from: https://cima.aemps.es/cima/dochtml/ft/64825/FT_64825.html. 3. Torsades de Pointes Following Clarithromycin Treatment [Internet]. Medscape [citado 2021 ago 10];Available from: http://www.medscape.com/viewarticle/813433. 4. Albert RK, Schuller JL. Macrolide Antibiotics and the Risk of Cardiac Arrhythmias. Am J Respir Crit Care Med 2014;189(10):1173-80. 5. Rodriguez-Duplat MC, et al. Guía para el diagnóstico y tratamiento de faringoamigdalitis aguda bacteriana. Asociación Colombiana de otorrinolaringología (ACORL). 2016. 6. Metlay JP, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019. 7. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021. 8. Uzun S, Djamin RS, Kluytmans JAJW, Mulder PGH, van’t Veer NE, Ermens AAM, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine 2014. 9. Table of Contents – STI Treatment Guidelines [Internet]. 2021 [citado 2021 ago 10];Available from: https://www.cdc.gov/std/treatment-guidelines/toc.htm. 10. MSPS-Colciencias-IETS. Guía de Práctica Clínica para el abordaje sindrómico del diagnóstico y tratamiento de los pacientes con infecciones de transmisión sexual y otras infecciones del tracto genital. 2013.

REFERENCIAS: 1. Data On File Novamed. 2. Ferrochel®. Equisalud [citado 2021 jul 2];Available from: https://www.equisalud.com/es-es/componentes/ferrochel/. 3. Pubchem Ferrochel. 4. Perez M LJ, Tobón G. COMPUESTOS DE HIERRO PARA SUPLEMENTACIÓN ORAL: PRINCIPIOS Y AVANCES -REVISIÓN SISTEMATICA. Vitae 2006. 5. Bovell-Benjamin AC, Viteri FE, Allen LH. Iron absorption from ferrous bisglycinate and ferric trisglycinate in whole maize is regulated by iron status. The American Journal of Clinical Nutrition 2000. 6. PubChem. Ferrous sulfate [Internet]. [citado 2021 ago 5];Available from: https://pubchem.ncbi.nlm.nih.gov/compound/24393. 7. PubChem. Iron saccharate [Internet]. [citado 2021 ago 5];Available from: https://pubchem.ncbi.nlm.nih.gov/compound/11377634. 8. PubChem. Iron polymaltose [Internet]. [citado 2021 ago 9];Available from: https://pubchem.ncbi.nlm.nih.gov/compound/76960246
. 9. Lozoff B. Iron Deficiency and Child Development. Food and Nutrition Bulletin. 2007. 10. Cusick S, Georgieff M, Rao R. Approaches for Reducing the Risk of Early-Life Iron Deficiency-Induced Brain Dysfunction in Children. Nutrients. 2018. 11. Stanco GG. Funcionamiento intelectual y rendimiento escolar en niños con anemia y deficiencia de hierro. Colombia médica. 2007. 12. ENSIN 2015. ICBF, INS, Minsalud. Resultados Pubublicados en : http://www.ensin.gov.co/Documents/Resultados-generales-ENSIN-2015-preliminar.pdf 13. INS, Martha Ospina. Presentación de resultados ENSIN 2015. 2019. Disponible en: https://www.ins.gov.co/Noticias/PublishingImages/Paginas/Mal- nutricion-oculta-colombia/MALNUTRICION-OCULTA-DRA-MARTHA-OSPINA.pdf#search=ensin.

REFERENCIAS: 1. Debbaneh PM, et al. Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-analysis. Otolaryngology–Head and Neck Surgery. 2019. 2. Bousquet J, et al. Patient response to AZE-Flu in an allergen exposure chamber. Poster presented at the EAACI congress. 2018. 3. Brożek JL, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. Journal of Allergy and Clinical Immunology. 2017. 4. Wise SK, et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis: ICAR: Allergic Rhinitis. International Forum of Allergy & Rhinology. 2018. 5. Scadding G, et al. Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis. Rhinology journal. 2019.

REFERENCIAS: 1. Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J. 1999. 2. Bolon MK. The Newer Fluoroquinolones. Medical Clinics of North America. 2011. 3. Strahilevitz J, Hooper DC. Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin. Antimicrobial Agents and Chemotherapy. 2005. 4. Rosenfeld RM, et al. Clinical Practice Guideline (Update): Adult Sinusitis. Otolaryngology–Head and Neck Surgery 2015. 5. Wispelwey B, Schafer KR. Fluoroquinolones in the management of community-acquired pneumonia in primary care. Expert Review of Anti-infective Therapy. 2010. 6. Kuzman I, et al. Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI). BMC Pulmonary Medicine. 2014. 7. Liu K-X, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis. J Thorac Dis. 2014.

REFERENCIAS: 1. Lactobacillus acidophilus, DDS®-1 | Chr. Hansen [Internet]. [citado 2021 jun 30];Available from: https://www.chr-hansen.com/es/human-health-and-probiotics/our-probiotic-strains/dds. 2. Data on file. Novamed S.A. . 3. Rivero JLG. Actualización en el conocimiento del microbioma en el asma.
4. Yan F, Polk DB. Probiotics and immune health: Curr Opin Gastroenterol 2011. 5. Gerasimov SV, Vasjuta VV, Myhovych OO, Bondarchuk LI. Probiotic Supplement Reduces Atopic Dermatitis in Preschool Children: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Am J Clin Dermatol 2010. 6. Chung KF. Airway microbial dysbiosis in asthmatic patients: A target for prevention and treatment? J Allergy Clin Immunol 2017. 7. Vemuri R, et al. Lactobacillus acidophilus DDS-1 Modulates Intestinal-Specific Microbiota, Short-Chain Fatty Acid and Immunological Profiles in Aging Mice. Nutrients 2019. 8. Meyer D, Stasse-Wolthuis M. The bifidogenic effect of inulin and oligofructose and its consequences for gut health. Eur J Clin Nutr 2009. 9. Olveira G, González-Molero I. Actualización de probióticos, prebióticos y simbióticos en nutrición clínica. Endocrinol Nutr 2016;63(9):482-94. 10. Guarner F. Probiotics and Prebiotics | World Gastroenterology Organisation [Internet]. [citado 2021 mar 23];Available from: https://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics. 11. Camacho JH, Rusinky Pinilla L, Salazar Peña D, Sanabria Dueñas S, Rojas Carvajal D, Burbano Castillo N, et al. Microbiota intestinal en pediatría. Rev Repert Med Cir 2020.

REFERENCIAS: 1. Prescott LF. Paracetamol: past, present, and future. Am J Ther. 2000. 2. Esh CJ, et al.. Acetaminophen (Paracetamol): Use beyond Pain Management and Dose Variability. Frontiers in Physiology. 2017.

REFERENCIAS: 1. Gillard M, et al. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflammation Research. 2005. 2. del Cuvillo A, et al. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006. 3. Anthes JC, Gilchrest H, Richard C, Eckel S, Hesk D, West RE, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol. 2002. 4. Devillier P, et al. Clinical Pharmacokinetics and Pharmacodynamics of Desloratadine, Fexofenadine and Levocetirizine: A Comparative Review. Clinical Pharmacokinetics. 2008. 5. Web C. Farmacología: AGONISMO INVERSO [Internet]. Farmacología. 2015. Disponible en: http://defarmacologia.blogspot.com.co/2015/10/agonismo-inverso.html. 6. BILASTINA, 7 RUPATADINA

REFERENCIAS: 1. Brożek JL, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. Journal of Allergy and Clinical Immunology. 2016. 2. Hatton RC, et al. Ambulatory Care: Efficacy and Safety of Oral Phenylephrine: Systematic Review and Meta-Analysis. Ann Pharmacother 2007;41(3):381-90.

REFERENCIAS: 1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention GINA 2019. 2019 2. Wise SK, et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis: ICAR: Allergic Rhinitis. International Forum of Allergy & Rhinology. 2018. 3. Erdoğan BA. Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination. The Turkish Journal of Ear Nose and Throat. 2014 4. Ciebiada M, et al. Use of Montelukast Alone or in Combination with Desloratadine or Levocetirizine in Patients with Persistent Allergic Rhinitis. American Journal of Rhinology & Allergy. 2011. 5. Wentzel JL, et al. Leukotriene Antagonists in Nasal Polyposis: A Meta-analysis and Systematic Review. Am J Rhinol & Allergy. noviembre de 2013;27(6):482–9. 6. Di Lorenzo G, et al. Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review. J Asthma Allergy. 2008. 7. Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clinical & Experimental Allergy. 2004. 8. Brożek JL, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. Journal of Allergy and Clinical Immunology. 2017. 9. Davis BE, et al. Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen. Journal of Allergy and Clinical Immunology. 2005. 10. Canonica GW, Blaiss M. Antihistaminic, Anti-Inflammatory, and Antiallergic Properties of the Nonsedating Second-Generation Antihistamine Desloratadine: A Review of the Evidence: World Allergy Organization Journal. 2011. 11. del Cuvillo A, et al. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006.

REFERENCIAS: 1. Data on file Novamed S.A. 2. Esplugues Juan V, Martí-Cabrera Miguel. Seguridad e interacciones de los IBP. Versión impresa ISSN 0016-3503 Gen v.64 n. 3 Caracas sep.2010: 221-227. 3. Horn J. Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors—focus on pKa and metabolism. Aliment Pharmacol Therapeut Symp 2006;2:340–50. 4. June Zhao, MD, PhD; Jianguo Li, PhDl; et al. Pharmacokinetic Properties of Esomeprazole in Children Aged 1 to 11 Years with Symptoms of Gastroesophageal Reflux Disease: A Randomized, Open-Label Study. Clinical Therapeutics/ Volumen 28, Number 11, 2006. 5. Co-Chairs: Yvan Vandenplas and Colin D. Rudolph. Committee Members: Carlo Di Lorenzo, Eric Hassall, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). Journal of Pediatric Gastroenterology and Nutrition 49:498–547 # 2009 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr, Vol. 49, No. 4, October 2009. 6. Lien H-C, Wang C-C, Lee S-W, Hsu J-Y, Yeh H-Z, Ko C-W, et al. Responder Definition of a Patient-Reported Outcome Instrument for Laryngopharyngeal Reflux Based on the US FDA Guidance. Value in Health. 2015;18(4):396-403.

REFERENCIAS: 1. Oka S, et al. N -Acetylcysteine suppresses TNF-induced NF-¬kB activation through inhibition of I¬B kinases. FEBS Letters. 2000. 2. Khomich O, et al. Redox Biology of Respiratory Viral Infections. Viruses. 2018. 3. Poe FL, Corn J. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. Medical Hypotheses. 2020. 4. Devaux CA, Retal. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? International Journal of Antimicrobial Agents. 2020. 5. DeDiego ML, et al. Inhibition of NF-kB-Mediated Inflammation in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice Increases Survival. Journal of Virology. 2014.

REFERENCIAS: 1. Marzatico F. Evaluation of tolerability power of keeping the oral bacterial load under control, of a mouth rinse. Universidad de Pavia20 Octubre 1999. 2. Buchsel PC. GelClair® oral gel. Clin Oncol Nursing 2003;7(1): 109-10. 3. Pogrel MA, Pham HD, Guntenhoner M, et al. Profile of hyaluronidase activity distinguishes carbon diosxide laser from scalpel wound healing. Ann Surg 1993;217(2):196-200. 4. MKroes BH, Beukelman CJ, Van Den Berg AJ, Wolbink, et al: Inhibition of human complement by beta-glycyrrhetinic acid. Immunology 1997;90(1):115-20.

REFERENCIAS: 1. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Ashok Kumar K, Kramper M, et al. Clinical Practice Guideline (Update): Adult Sinusitis. Otolaryngology–Head and Neck Surgery. 2015. 2. European commission. Cosing. http://ec.europa.eu/ growth/tools-databases/cosing/index.cfm?fuseaction=search.details_v2&id=340402. 3. Data on file Novamed S.A.

REFERENCIAS: 1. PubChem. Allantoin [Internet]. Disponible en: https://pubchem.ncbi.nlm.nih.gov/compound/204. 2. Ali S, Wahbi W. The efficacy of aloe vera in management of oral lichen planus: a systematic review and meta-analysis. Oral Diseases. 2017. 3. Kumar R, et al. Therapeutic potential of Aloe vera-A miracle gift of nature. Phytomedicine. 2019. 4. Rieger MM. Cosmetics. En: John Wiley & Sons, Inc., editor. Kirk-Othmer Encyclopedia of Chemical Technology [Internet]. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2009. 5. McCormick CL, Lowe AB, Ayres N. Water-Soluble Polymers. En: John Wiley & Sons, Inc., editor. Encyclopedia of Polymer Science and Technology [Internet]. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2004.
6. PubChem. Glycerol [Internet]. Disponible en: https://pubchem.ncbi.nlm.nih.gov/compound/753 7. PubChem. Bicarbonate [Internet]. Disponible en: https://pubchem.ncbi.nlm.nih.gov/compound/769.

REFERENCIAS: 1.INVIMA. Registro sanitario Irtal 20 mg. MSPS; 2017. 2. Galie N, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal. 2009. 3. Galiè N, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Heart Journal. 2016. 4. Beltrán-Gámez ME, Sandoval-Zárate J, Pulido T. Inhibidores de fosfodiesterasa-5 para el tratamiento de la hipertensión arterial pulmonar. Archivos de Cardiología de México. 2015. 5. PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension. clinicaltrials.gov. 2018. 6. PHIRST 2. Oudiz RJ, et al. Tadalafil for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology. 2012. 7. Galiè N, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine. 2015.

REFERENCIAS: 1. Data On file KOACT. Novamed S.A. 2. Rosenfeld RM, et al. Clinical Practice Guideline (Update): Adult Sinusitis. Otolaryngol Neck Surg. 2015. 3. Chow AW, et al. Executive Summary: IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. Clinical Infectious Diseases. 2012. 4. Mandell LA, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases. 2007. 5. Lieberthal AS, et al. The Diagnosis and Management of Acute Otitis Media. Pediatrics. 2013. 6. Carreño J, Domínguez M. Mordedura humana y por animales. Guías para manejo de urgencias. Tercera edición. Bogotá: Ministerio de la Protección Social de Colombia. 2009.

REFERENCIAS: 1. Cuzzocrea S et al. Pharmacological and clinical overview of cloperastine in treatment of cough. Therapeutics and Clinical Risk Management. 2011. 2. Aliprandi P. et al. Levocloperastine in the treatment of chronic nonproductive cough: comparative efficacy versus standard antitussive agents. Drugs Exp Clin Res. 2004. 3. Chung KF, Widdicombe J, Belvisi MG, editores. Pharmacology and therapeutics of cough. Berlin: Springer; 2009. (Handbook of experimental pharmacology). 4. Aliprandi P. et al. Therapeutic Use of Levocloperastine as an Antitussive Agent. Clinical Drug Investigation. el 1 de abril de 2002. 5. Catania MA, Cuzzocrea S. Pharmacological and clinical overview of cloperastine in treatment of cough. Therapeutics and Clinical Risk Management. 2011. doi:10.2147/TCRM.S16643. 6. NOVAMED. Ficha técnica Levronc. 2017.

REFERENCIAS: 1. Bender BG. Motivating Patient Adherence to Allergic Rhinitis Treatments. Current Allergy and Asthma Reports. 2015. 2. Data On File Novamed. 3. PubChem. N-Vinyl-2-pyrrolidone disponible en: https://pubchem.ncbi.nlm.nih.gov/compound/6917 4. European commission. Cosing. http://ec.europa.eu/ growth/tools-databases/cosing/index.cfm?fuseaction=search.details_v2&id=340402. 5. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical Practice Guideline: Allergic Rhinitis. Otolaryngology-Head and Neck Surgery. 2015. 6. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Ashok Kumar K, Kramper M, et al. Clinical Practice Guideline (Update): Adult Sinusitis. Otolaryngology–Head and Neck Surgery. 2015. 7. Gupta V, Gupta M, Matreja PS, Singh S. Efficacy of Mometasone Nasal Spray in Children with Snoring due to Adenoids. Gupta A, editor. Clinical Rhinology An International Journal. 2014.

REFERENCIAS: 1. Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opinion on Drug Metabolism & Toxicology. 2008. 2. Yamaya M, Nishimura H, Nadine LK, Ota C, Kubo H, Nagatomi R. Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Archives of Pharmacal Research. 2014. 3. Chenot J-F, Weber P, Friede T. Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis. BMC Family Practice [Internet]. 2014 . Disponible en: http://bmcfampract.biomedcentral.com/articles/10.1186/1471-2296-15-45 4. de Mey C, Patel J, Lakha D, Richter E, Koelsch S. Efficacy and Safety of an Oral Ambroxol Spray in the Treatment of Acute Uncomplicated Sore Throat. Drug Research. 2015.

REFERENCIAS: 1. https://www.drugs.com/mtm_esp/loratadine.html 2. Noscapine [Internet]. [citado el 3 de mayo de 2018]. Disponible en: https://www.drugbank.ca/drugs/DB06174. 3. Salbutamol https://www.drugs.com/uk/salbutamol-syrup-2mg-5ml-leaflet.html.

REFERENCIAS: 1.Jaruvongvanich V, et al. Extranasal symptoms of allergic rhinitis are difficult to treat and affect quality of life. Allergology International. 2016. 2. Lieberman P. Intranasal antihistamines for allergic rhinitis: Mechanism of action. Allergy and Asthma Proceedings. 2009. 3. Ratner PH, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Annals of Allergy, Asthma & Immunology. 2005. 4. Smith PK, Collins J. Olopatadine 0.6% Nasal Spray Protects from Vasomotor Challenge in Patients with Severe Vasomotor Rhinitis. American Journal of Rhinology & Allergy. 2011. 5. del Cuvillo A, et al. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006.

REFERENCIAS: 1.Data on file Novamed S.A. 2. Lucas-Bouwman ME. Short report: Crushed prednisolone tablets or oral solution for acute asthma? Archives of Disease in Childhood. 2001. 3. Castro-Rodríguez JA, Beckhaus AA, Forno E. Efficacy of oral corticosteroids in the treatment of acute wheezing episodes in asthmatic preschoolers: Systematic review with meta-analysis: Efficacy of Oral Corticosteroids in Acute Wheezing. Pediatric Pulmonology. agosto de 2016. 4. Castro-Rodriguez JA. El uso de corticoides orales en pediatria. Charla magistral. Archivo novamed. marzo 2017. 5. Comparativo de concentración de Pepred plus vs concentración de competencia por la dosis recomendada en la literatura. Versión nuestra. 6. Bhogal SK, et al. Early Administration of Systemic Corticosteroids Reduces Hospital Admission Rates for Children With Moderate and Severe Asthma Exacerbation. Annals of Emergency Medicine. 2012. 7. Global initiative for asthma. global strategy for asthma management and prevention. GINA 2021 8. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. Edinburgh: SIGN; 2016 9. MSPS, Asociación Colombiana de Neumología Pediátrica. Guía de práctica clínica para el diagnóstico, atención integral y seguimiento de niños y niñas con diagnóstico de Asma. 2013 10. Registro INVIMA Pepred-Pepred Plus.

REFERENCIAS: 1. Data On File. Novamed. 2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. Disponible en: www.ginasthma.org. 3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report. Disponible en: www.goldcopd.org. 4. Wedzicha JA, Miravitlles M, Hurst JR, Calverley PMA, Albert RK, Anzueto A, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal. 2017. 5. Corticosteroids [Internet]. COVID-19 Treatment Guidelines [citado 2021 jun 30];Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/corticosteroids/. 6. Plaza G, Durio E, Herráiz C, Rivera T, García-Berrocal JR. Consenso sobre el diagnóstico y tratamiento de la sordera subita. Acta Otorrinolaringológica Española. 2011. 7. Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia, Kordiš Š, University of Ljubljana School of Medicine, Ljubljana, Slovenia, Vozel D, Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia, University of Ljubljana School of Medicine, Ljubljana, Slovenia, et al. The Outcome of Prompt Concomitant Single-Dose High-Concentration Intratympanic and Tapered Low-Dose Oral Systemic Corticosteroid Treatment for Sudden Deafness. Int Adv Otol 2020. 8. Garrido AM, Gonzalez E, Pinós PJ, Gil I. Parálisis facial periférica. Medicina Integral. Vol 36 Num 8. 2000. 9. Baugh RF, Basura GJ, Ishii LE, Schwartz SR, Drumheller CM, Burkholder R, et al. Clinical Practice Guideline: Bell’s Palsy. Otolaryngol Head Neck Surg 2013. 10. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Ashok Kumar K, Kramper M, et al. Clinical Practice Guideline (Update): Adult Sinusitis. Otolaryngology–Head and Neck Surgery. 2015. 11. Fokkens W.J., Lund V.J. , Hopkins C., Hellings P.W., Kern R., Reitsma S., et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020 Rhinology. 2020.

REFERENCIAS: 1. Ammonium chloride [Internet]. [citado el 3 de mayo de 2018]. Disponible en: https://www.drugbank.ca/drugs/DB06767. 2. Noscapine [Internet]. [citado el 3 de mayo de 2018]. Disponible en: https://www.drugbank.ca/drugs/DB06174. 3. Fenoterol [Internet]. [citado el 3 de mayo de 2018]. Disponible en: https://www.drugbank.ca/drugs/DB01288.

REFERENCIAS: 1. Revisión de artículos en publicados EMBASE, a junio 2021. 2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management,and prevention of chronic obstructive pulmonary disease. 2021 report. Disponible en: www.goldcopd.org. 3. Bronsky EA, et al. Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults. Current Medical Research and Opinion 2004. 4. Molimard M, et al. Assessment of Handling of Inhaler Devices in Real Life: An Observational Study in 3811 Patients in Primary Care. Journal of Aerosol Medicine 2003. 5. Molimard M. How to achieve good compliance and adherence with inhalation therapy. Current Medical Research and Opinion 2005.

REFERENCIAS: 1. Drug bank. Alizapride. Septiembre 2018. https://www.drugbank.ca/drugs/DB01425. 2. Carcassonne M. [Effectiveness of alizapride against emesis in infants and children (author’s transl)]. Sem Hop 1982. 3. Kassi M. [The value of alizapride in the treatment of vomiting in infants and children]. Ann Pediatr (Paris) 1990. 4. Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M. Activity of a new antiemetic agent: alizapride: A randomized double-blind crossover controlled trial. Cancer Chemother Pharmacol.1988. 5. Dani, R. et al. Antiemetic effect of alizapride: a multicenter evaluation of 1,945 cases. Folha méd. 1990.

REFERENCIAS: 1. Ministerio de salud y de la protección social. Estrategia nacional para la prevención y control de las deficiencias de micronutrientes en Colombia 2014-2021. Disponible en:
https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/SNA/Estrategia-nacional-prevencion-control-deficiencia-micronutrientes.pdf. 2. ENSIN 2015. ICBF, INS, Minsalud. Resultados Pubublicados en : http://www.ensin.gov.co/Documents/Resultados-generales-ENSIN-2015-preliminar.pdf. 3. INS, Martha Ospina. Presentación de resultados ENSIN 2015. 2019. Disponible en: https://www.ins.gov.co/Noticias/ PublishingImages/Paginas/Malnutricion-oculta- colombia/MALNUTRICION-OCULTA-DRA-MARTHA-OSPINA.pdf#search=ensin. 4. Jothimani D, Kailasam E, Danielraj S, Nallathambi B, Ramachandran H, Sekar P, et al. COVID-19: Poor outcomes in patients with zinc deficiency. International Journal of Infectious Diseases 2020. 5. Wessels I, Rolles B, Rink L. The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis. Front Immunol 2020. 6. Skalny A, Rink L, Ajsuvakova O, Aschner M, Gritsenko V, Alekseenko S, et al. Zinc and respiratory tract infections: Perspectives for COVID‑19 (Review). Int J Mol Med [Internet] 2020 [citado 2020 oct 15];Available from: http://www.spandidos-publications.com/10.3892/ijmm.2020. 7. Sheikh A, Shamsuzzaman S, Ahmad SM, Nasrin D, Nahar S, Alam MM, et al. Zinc Influences Innate Immune Responses in Children with Enterotoxigenic Escherichia coli-Induced Diarrhea. The Journal of Nutrition. 2010. 8. Bonaventura P, Benedetti G, Albarède F, Miossec P. Zinc and its role in immunity and inflammation. Autoimmunity Reviews 2015. 9. Nishi Y. Zinc and growth. Journal of the American College of Nutrition 1996. 10. MacDonald RS. The Role of Zinc in Growth and Cell Proliferation. The Journal of Nutrition 2000. 11. Kelishadi R. Effects of zinc supplementation on subscales of anorexia in children: A randomized controlled trial. Pakistan Journal of Medical Sciences. 2014. Disponible en: http://pjms.com.pk/index.php/pjms/article/view/6377. 12. Organización Panamericana de la Salud (OPS). Cuadro de procedimientos Atención Integrada de las enfermedades prevalentes de la infancia (AIEPI). 2010. 13. Dalfa RA, El Aish KIA, El Raai M, El Gazaly N, Shatat A. Oral zinc supplementation for children with acute diarrhoea: a quasi-experimental study. The Lancet. 2018.